Arovella Therapeutics Study Demonstrates CLDN18.2 CAR-T Cells Eliminate Pancreatic Cancer Cells, Shares Jump Over 13%

MT Newswires Live

Oct 02, 2025

Arovella Therapeutics (ASX:ALA) confirmed the functionality of its claudin 18.2 (CLDN18.2)-targeting chimeric antigen receptor by demonstrating that CLDN18.2 chimeric antigen receptor-T (CAR-T) cells eliminate pancreatic cancer cells that express CLDN18.2 in a proof-of-concept in vitro study, according to a Thursday Australian bourse filing.

Arovella's chimeric antigen receptor design is based on the patent-protected CLDN18.2 antigen-binding sequences of the SPX-101 monoclonal antibody, for which the firm has an exclusive license for use in cell therapies.

The study was performed at the University of North Carolina. The human pancreatic adenocarcinoma cell line, PaTu8892S, which expresses CLDN18.2, was selected as a model cell line for this study. CLDN18.2 CAR-T cells, generated from three independent donors, were cultured in vitro with twice the number of PaTu8892S cells for three days. After this, the degree of cytotoxicity was measured.

The firm's shares jumped over 13% in recent trading on Thursday.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2572672375"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2572672375\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2572672375?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-02 10:21","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2572672375","market":"us","top_or_hot":-1,"title":"Arovella Therapeutics Study Demonstrates CLDN18.2 CAR-T Cells Eliminate Pancreatic Cancer Cells, Shares Jump Over 13%","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/ARVEF\">Arovella Therapeutics</a> (ASX:ALA) confirmed the functionality of its claudin 18.2 (CLDN18.2)-targeting chimeric antigen receptor by demonstrating that CLDN18.2 chimeric antigen receptor-T (CAR-T) cells eliminate pancreatic cancer cells that express CLDN18.2 in a proof-of-concept in vitro study, according to a Thursday Australian bourse filing.</p><p>Arovella's chimeric antigen receptor design is based on the patent-protected CLDN18.2 antigen-binding sequences of the SPX-101 monoclonal antibody, for which the firm has an exclusive license for use in cell therapies.</p><p>The study was performed at the University of North Carolina. The human pancreatic adenocarcinoma cell line, PaTu8892S, which expresses CLDN18.2, was selected as a model cell line for this study. CLDN18.2 CAR-T cells, generated from three independent donors, were cultured in vitro with twice the number of PaTu8892S cells for three days. After this, the degree of cytotoxicity was measured.</p><p>The firm's shares jumped over 13% in recent trading on Thursday.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Arovella Therapeutics Study Demonstrates CLDN18.2 CAR-T Cells Eliminate Pancreatic Cancer Cells, Shares Jump Over 13%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nArovella Therapeutics Study Demonstrates CLDN18.2 CAR-T Cells Eliminate Pancreatic Cancer Cells, Shares Jump Over 13%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-10-02 10:21</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/ARVEF\">Arovella Therapeutics</a> (ASX:ALA) confirmed the functionality of its claudin 18.2 (CLDN18.2)-targeting chimeric antigen receptor by demonstrating that CLDN18.2 chimeric antigen receptor-T (CAR-T) cells eliminate pancreatic cancer cells that express CLDN18.2 in a proof-of-concept in vitro study, according to a Thursday Australian bourse filing.</p><p>Arovella's chimeric antigen receptor design is based on the patent-protected CLDN18.2 antigen-binding sequences of the SPX-101 monoclonal antibody, for which the firm has an exclusive license for use in cell therapies.</p><p>The study was performed at the University of North Carolina. The human pancreatic adenocarcinoma cell line, PaTu8892S, which expresses CLDN18.2, was selected as a model cell line for this study. CLDN18.2 CAR-T cells, generated from three independent donors, were cultured in vitro with twice the number of PaTu8892S cells for three days. After this, the degree of cytotoxicity was measured.</p><p>The firm's shares jumped over 13% in recent trading on Thursday.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2572672375","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2572672375","pubTimestamp":1759371693,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Arovella Therapeutics  confirmed the functionality of its claudin 18.2 -targeting chimeric antigen receptor by demonstrating that CLDN18.2 chimeric antigen receptor-T  cells eliminate pancreatic cancer cells that express CLDN18.2 in a proof-of-concept in vitro study, according to a Thursday Australian bourse filing.Arovella's chimeric antigen receptor design is based on the patent-protected CLDN18.2 antigen-binding sequences of the SPX-101 monoclonal antibody, for which the firm has an exclusive license for use in cell therapies.The study was performed at the University of North Carolina. The human pancreatic adenocarcinoma cell line, PaTu8892S, which expresses CLDN18.2, was selected as a model cell line for this study. CLDN18.2 CAR-T cells, generated from three independent donors, were cultured in vitro with twice the number of PaTu8892S cells for three days. After this, the degree of cytotoxicity was measured.The firm's shares jumped over 13% in recent trading on Thursday.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","BK4022":"陆运","CAR":"安飞士","BK7096":"制药","BK4539":"次新股","BK4230":"旅客陆运","BK4139":"生物科技","ALA.AU":"AROVELLA THERAPEUTICS LTD","LENZ":"Therapeutics"},"translate_title":"Arovella Therapeutics研究证明CLDN18.2 CAR-T细胞可消除胰腺癌细胞，股价大涨超13%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LENZ":1.5,"CAR":1.5,"ALA.AU":1},"content_text":"Arovella Therapeutics (ASX:ALA) confirmed the functionality of its claudin 18.2 (CLDN18.2)-targeting chimeric antigen receptor by demonstrating that CLDN18.2 chimeric antigen receptor-T (CAR-T) cells eliminate pancreatic cancer cells that express CLDN18.2 in a proof-of-concept in vitro study, according to a Thursday Australian bourse filing.Arovella's chimeric antigen receptor design is based on the patent-protected CLDN18.2 antigen-binding sequences of the SPX-101 monoclonal antibody, for which the firm has an exclusive license for use in cell therapies.The study was performed at the University of North Carolina. The human pancreatic adenocarcinoma cell line, PaTu8892S, which expresses CLDN18.2, was selected as a model cell line for this study. CLDN18.2 CAR-T cells, generated from three independent donors, were cultured in vitro with twice the number of PaTu8892S cells for three days. After this, the degree of cytotoxicity was measured.The firm's shares jumped over 13% in recent trading on Thursday.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}